Search clinical trials for: Blood Coagulation Factor Inhibitors

Total 15222 results

Sohag University

Completed

Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

Covid19

Egypt
CSL Behring

Completed

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Blood Coagulation Disorders | Blood Platelet Disorders | Hematologic Disease | Von Willebrand Disease

United States
Northwestern University

Completed

Coagulation Factor Changes Associated With Postpartum Hysterectomies

Hemorrhage | Obstetric Labor Complications | Complications; Cesarean Section

United States
Catalyst Biosciences

Completed

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Hemophilia B

South Africa
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Hemophilia B
Bio Products Laboratory

Completed

A Study Investigating Treatment Factor X in People With Factor X Deficiency

Factor X Deficiency

United States, Turkey, Germany, Spain, United Kingdom
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
Shandong Provincial Hospital

Recruiting

Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study (MA)

Gastric Cancer Stage | Lymph Node Metastasis

China
Sohag University

Recruiting

Rare Inherited Bleedig Disorders in Children at Sohag University Hospital

Rare Inherited Bleeding Disorders in Children at Sohag University Hospital

Egypt
Laboratoire français de Fractionnement et de Biotechnologies

No longer available

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency (EAP)

Surgery | Postpartum Hemorrhage | Wound; Rupture, Surgery, Cesarean Section

United States
Institut Bergonié

Completed

Hypercoagulability After Breast Cancer Surgery (EHC)

Breast Cancer | Blood Coagulation Disorders

France
Rabin Medical Center

Completed

The Effect of In Vitro Fertilization on Coagulation Parameters as Measured by Thromboelastogram

Fertilization in Vitro and Blood Coagulation Factors

Israel
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
Pfizer

Completed

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Hemophilia B

Korea, Republic of
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

vonWillebrand's Disease

Israel
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Masaryk Hospital Krajská zdravotní a.s.

Completed

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

Coagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor Deficiency

Czechia
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
University of Modena and Reggio Emilia

Completed

Thromboelastographic Guide for Blood Products in Cirrhotics

Liver Cirrhosis | Coagulation Disorder
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
Eio Biomedical Ltd.

Completed

Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System

Reduction of Postoperative Adhesions

Lithuania
Laboratoire français de Fractionnement et de Biotechnologies

Recruiting

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM)

Hemophilia

United States, Thailand, Malaysia, Mexico, South Africa, Turkey
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Baxalta now part of Shire

Completed

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Hemophilia B

Korea, Republic of
Hospital General Universitario Gregorio Marañon

Completed

Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy (ISBIDCM)

Stroke | Thrombosis | Dilated Cardiomyopathy

Spain
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Sohag University

Not yet recruiting

Burden of Respiratory Illnesses in Pediatric Intensive Care Unit and Predictors of Mortality

Respiratory Illnesses

Egypt
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
Hospital General Universitario Gregorio Marañon
Hospital Clinic of Barcelona; University of Salamanca

Recruiting

Intraventricular Stasis In Cardiovascular Disease (ISBIFLOW)

Stroke | Dilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Thrombosis Cardiac

Spain
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
Sohag University

Not yet recruiting

Clinical,Endoscopic and Radiological Assessment of Portal Hypertension in Children With Chronic Liver Diseases

Portal Hypertension

Egypt
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
American Thrombosis and Hemostasis Network
LFB USA, Inc.

Recruiting

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Second Affiliated Hospital, School of Medicine,...

Recruiting

Inflammation and Coagulation Factors for Predicting Cerebral Edema After SAH

Inflammation | Cerebral Edema | Coagulation and Hemorrhagic Disorders

China
Christian Medical College, Vellore, India
Dr. H. Trent Spencer, Professor, Emory University of Medicine, Atlanta Ga...

Recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A

India
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
Baxalta now part of Shire

Completed

China ADVATE PTP Study

Hemophilia A

China
Assiut University

Not yet recruiting

TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis

Lupus Nephritis

Search clinical trials for: Blood Coagulation Factor Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations